Astrazeneca (AZN) - News Mentions

Sign up to add (AZN) to your portfolio and access more historical data.

20%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Johnson & Johnson
Johnson & Johnson
JNJ		 1 0%
Eli Lilly and Company
Eli Lilly and Company
LLY		 0 100%
Pfizer
Pfizer
PFE		 3 0%
AbbVie
AbbVie
ABBV		 0 100%
TherapeuticsMD
TherapeuticsMD
TXMD		 0 0%
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman
January 20
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
January 20
Brooklyn Investment Group Grows Position in AstraZeneca PLC (NASDAQ:AZN)
January 20
Gateway Investment Advisers LLC Sells 1,754 Shares of AstraZeneca PLC (NASDAQ:AZN)
January 20
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
January 19
Carnegie Investment Counsel Lowers Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)
January 19
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
January 18
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
January 17
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption – Hagens Berman
January 17
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
January 17
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 – AZN
January 17
Contact Levi & Korsinsky by February 21, 2025 Deadline to Join Class Action Against AstraZeneca PLC (AZN)
January 16
AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
January 15
AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights – AZN
January 15
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Moody National Bank Trust Division
January 15
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action
January 13

Month over Month

Est. daily news mentions.

Dec 2024 2
Nov 2024 3
Oct 2024 2
Sep 2024 3
Aug 2024 2

How often is Astrazeneca mentioned in the news?

Astrazeneca was mentioned an estimated 2 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Astrazeneca performing compared to its industry peers?

Astrazeneca overperforms a majority of its industry peers when it comes to News Mentions, ranking in the 67th percentile.

Has there been an increase or decrease in news mentions of Astrazeneca in the last month?

There has been no significant change in the number of news mentions for Astrazeneca's compared to the last month.

Why is it important to track news mentions for Astrazeneca?

By monitoring mentions in the news for Astrazeneca, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Astrazeneca, ultimately improving their investment strategies.

Sign up and get more insights on Astrazeneca.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact